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Abstract
Background: High glucose can induce apoptosis in vascular endothelial cells, which may contribute to the
development of vascular complications in diabetes. We evaluated the role of the death receptor pathway of
apoptotic signaling in high glucose-induced apoptosis in human coronary artery endothelial cells (HCAECs).
Methods: HCAECs were treated with media containing 5.6, 11.1, and 16.7 mM of glucose for 24 h in the presence
or absence of tumor necrosis factor (TNF)-a. For detection of apoptosis, DNA fragmentation assay was used.
HCAEC expression of death receptors were analyzed by the PCR and flow cytometry methods. Also, using
immunohistochemical techniques, coronary expression of death receptors was assessed in streptozotocin-
nicotinamide-induced type 2 diabetic mice.
Results: Exposure of HCAECs to high glucose resulted in a significant increase in TNF-R1 and Fas expression,
compared with normal glucose. High glucose increased TNF-a production by HCAECs and exogenous TNF-a up-
regulated TNF-R1 and Fas expression in HCAECs. High glucose-induced up-regulation of TNF-R1 and Fas expression
was undetectable in the presence of TNF-a. Treatment with TNF-R1 neutralizing peptides significantly inhibited
high glucose-induced endothelial cell apoptosis. Type 2 diabetic mice displayed appreciable expression of TNF-R1
and Fas in coronary vessels.
Conclusions: In association with increased TNF-a levels, the death receptors, TNF-R1 and Fas, are up-regulated in
HCAECs under high glucose conditions, which could in turn play a role in high glucose-induced endothelial cell
apoptosis.
Background
Vascular complications are a leading cause of morbidity
and mortality in diabetes. A wide variety of studies sug-
gest that endothelial dysfunction and damage present
pathophysiological early steps for the development of
vascular complications [1,2]. A growing body of evi-
dence indicates the close correlation between hypergly-
cemia and the abnormalities in endothelial function and
morphology. High ambient glucose has been shown to
disturb cell cycle [3,4], increase DNA damage [5], delay
endothelial cell replication [3], and cause excessive cell
death [3] in cultured human endothelial cells. More cri-
tically, that high glucose selectively triggers apoptosis in
cultured endothelial cells has been demonstrated by
subsequent studies from different laboratories [6-10].
An accelerated programmed cell death of retinal micro-
vascular cells has been reported to occur in situ in
human and experimental diabetic retinopathy [11,12].
Moreover, significant apoptosis of endothelial cells has
been found in ventricular myocardial biopsies obtained
from diabetic patients [13]. Several downstream path-
ways affected by hyperglycemia, such as oxidative stress
[8-10,14,15] and glycation [16,17], are thought to stimu-
late apoptosis in endothelial cells. In contrast to its
effect on endothelial cells, high glucose has been
reported to inhibit apoptosis in coronary artery smooth
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[18]. Thus, the molecular events linking high glucose
with the apoptotic machinery of endothelial cells may
be far more complicated than being realized.
Apoptotic cell death in mammals can proceed by two
distinct pathways that ultimately converge into a common
pathway causing the activation of the effector enzymes
caspases. The intrinsic pathway feeds cell death signals
through the mitochondrion, which appears to act as a
genetic damage sensor and monitor of metabolic status.
Thus, injured mitochondria can release cytochrome c into
the cytoplasm, where it can bind to apoptotic protease
activating factor (APAF)-1 and activate caspase networks
that induce apoptosis [19,20]. Recent report has shown
that exposure to high glucose results in a decrease in the
mitochondrial membrane potential and a release of cyto-
chrome c in human umbilical vein endothelial cells [21].
Furthermore, high glucose treatment has been found to
cause an increase in protein expression of Bax, whose
complex formation is associated with cytosolic release of
cytochrome c, in human aortic endothelial cells [22]. Proa-
poptotic signaling can also be mediated by the death
receptor pathway. This extrinsic pathway transduces the
signals of extracellular ‘death ligands’ which are members
of the tumor necrosis factor (TNF) superfamily. After
ligand binding to the intracellular death domain on the
receptors, including TNF receptor 1 (TNF-R1) and Fas,
the activated death receptors recruit adaptor proteins,
which in turn recruit procaspase-8 into a proapoptotic
complex termed the death-inducing signaling complex
(DISC). Then, the initiator procaspase-8 is activated pro-
teolytically into caspase-8 and further activates effector
caspases along the common pathway of apoptosis [23,24].
One study has revealed that reduced T cell Fas ligand
expression prevents diabetes in NOD mice [25], and sev-
eral similar studies have focused on the importance of Fas
in beta cell death and the development of diabetes [26,27],
although evidence against a role of Fas has also been pre-
sented [28,29]. Nevertheless, data about a potential role of
the death receptor apoptotic signaling pathway in the high
glucose-induced apoptotic process in endothelial cells are
still missing. Such information is important for under-
standing molecular mechanisms underlying high glucose-
induced endothelial cell apoptosis.
In the present study, we initially examined whether
high ambient glucose up-regulates expression of death
receptors in cultured human coronary artery endothelial
c e l l s( H C A E C s ) .W ef o u n dt h a tg e n ee x p r e s s i o nl e v e l s
of the death receptors, TNF-R1 and Fas, were strikingly
increased in endothelial cells under high-glucose condi-
tions. Next, we investigated the possible involvement of
the death receptor pathway of apoptotic signaling in
high glucose-induced apoptosis in endothelial cells.
Finally, we evaluated the possibility that coronary
arteriolar endothelium may significantly express TNF-R1
and Fas in type 2 diabetic mice.
Materials and methods
Endothelial cell culture
HCAECs were purchased from Cambrex Bioscience
(Walkersville, MD). Cells were used between passages 6
and 7 for experiments to avoid effects of in vitro cell
aging. Cells were grown in endothelial growth media-2
(EGM-2; Cambrex) supplemented with growth factors
and 5% (v/v) fetal bovine serum to 70-80% confluency.
Cells were cultured in a humidified incubator at 37°C
with a 5% CO2 atmosphere and the medium was chan-
ged every second day. To determine the effect of high
glucose or TNF-a on cell apoptosis and death receptor
expression, cells were incubated with both zero growth
factors and zero hydrocortisone for 30 h, and they were
then cultured for 24 h under different concentrations of
glucose (5.6, 11.1 and 16.7 mM).
Reverse transcription PCR (RT-PCR)
Total RNA was isolated from cells using standard proce-
dure, including ISOGEN (Nippon Gene, Tokyo, Japan).
The RNA was reverse-transcribed in a 20-μl reaction
mixture that contained 5 U ReverScript
® III (Wako,
Osaka, Japan) and 0.5 μg oligo(dT)12-18 primer (Invitro-
gen, Carlsbad, CA) at 42°C for 1 h, followed by 51°C for
30 min. The primer pairs for TNF-R1 (forward, 5’-GAG
AGG CCA TAG CTG TCT GG-3’; reverse, 5’-GTT CCT
TTG TGG CAC TTG GT-3’), for Fas (forward, 5’-TCA
GTA CGG AGT TGG GGA AG-3’; reverse, 5’-CAG
GCC TTC CAA GTT CTG AG-3’), for DR4 (forward, 5’-
AGA GAG AAG TCC CTG CAC CA-3’; reverse, 5’-GTC
ACT CCA GGG CGT ACA AT-3’), and for DR5 (for-
ward, 5’-CAC CAG GTG TGA TTC AGG TG-3’;
reverse, 5’-CCC CAC TGT GCT TTG TAC CT-3’)
yielded a 218-, 207-, 154-, and 221-bp PCR product,
respectively. Human b-actin (forward, 5’-GGA CTT
CGA GCA AGA GAT GG-3’;r e v e r s e ,5 ’-AGC ACT
GTG TTG GCG TAC AG-3’) was used as a reference
gene. PCR was performed using an iCycler (Bio-Rad,
Tokyo, Japan). The reaction mixture consisted of tem-
plate cDNA, 0.2 μMo fe a c hp r i m e r ,3 0 0μMd N T P s ,3
mM MgCl2, and 0.05 U/μl ExTaq DNA polymerase
(Takara Shuzo, Ohtsu, Japan). PCR was performed for 32
cycles for each gene with denaturation at 95°C for 15 s,
annealing at 61°C for 15 s, and extension at 72°C for 20 s.
PCR products were quantified using NIH Image.
Quantitative real-time PCR
Real-time PCR was performed in a final volume of 20 μl
containing cDNA template and primers using Takara
RNA PCR kit (Takara Shuzo) as described in the manu-
facture’s manual. PCR amplification was carried out on
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forward 5’-AAC AGA ACA CCG TGT GCA CCT-3’
and reverse 5’-AGT CCT CAG TGC CCT TAA CAT
TCT C-3’; FAS, forward 5’-AGA GTA AAT GCA GTG
GCA TGC TAA G-3’ and reverse 5’-GGG TTA GCC
TGT GGA TAG ACA TTT G-3’;D R 4 ,f o r w a r d5 ’-GGA
ACA CAG CAT GTC AGT GCA A-3’ and reverse 5’-
TGT CAC TCC AGG GCG TAC AAT C-3’;D R 5 ,f o r -
ward 5’-CAT CTA TGG ACA GGC TGG GAC A-3’
and reverse 5’-CCC AAA CAG GGC TCA AGT TCA-
3’;a n da c t i n ,f o r w a r d5 ’-TGG CAC CCA GCA CAA
TGA A-3’ and reverse 5’-CTA AGT CAT AGT CCG
CCT AGA AGC A-3’.T h eP C Rp r o g r a mc o n s i s t e do f
95°C for 30 s for initial denaturation of DNA, followed
by 40 cycles of 95°C for 5 s, 60°C for 34 s for annealing
of primers, and 95°C for 1 min for elongation. The PCR
product size for TNF-R1, FAS, DR4, DR5, and actin was
141, 150, 130, 96, and 186 bp, respectively; they were
visualized after agarose gel electrodes and ethidium bro-
mide staining. Actin served as an internal control for
normalization.
Immunocytochemistry and TUNEL staining
After being fixed with 4% paraformaldehyde for 15 min
at room temperature, cells were kept in PBS at 4°C until
staining. Unspecific binding sites were blocked in PBS
containing 10% normal goat sera. The samples were
treated with rabbit anti-human von Willebrand factor
(vWF) antibody (Chemicon, Temecula, CA) at 1:100
dilution overnight at 4°C, carefully washed and stained
with Alexa goat anti-rabbit secondary antibody (Invitro-
gen) at 1:500 dilution overnight at 4°C. For visualization
of endothelial cells, cells were incubated with biotiny-
lated Griffonia simplicifolia isolectin-B4 (Vector Labora-
tories, Burlingame, CA) overnight at 4°C, followed by an
overnight incubation at 4°C with streptavidin (Alexa
Fluor
® 488 conjugate; Invitrogen). The nucleus was
counterstained with Hoechst 33258 (Nakalai Tesque,
Kyoto, Japan). Immunofluorescent images were observed
under a Leica TCS-SP5 confocal sytem.
The terminal deoxynucleotide transferase-mediated
dUTP nick end labeling (TUNEL) technique was con-
ducted to detect apoptotic endothelial cells. The fluores-
cein in situ cell death detection kit (DeadEnd™
Fluorometric TUNEL System; Promega, Madison, WI)
was used according to the manufacturer’si n s t r u c t i o n s .
The fluorosein-labeled cells undergoing apoptosis were
recognized as a green fluorescent nucleus. The samples
were analyzed using a fluorescence microscope.
DNA fragmentation assay
To determine the extent of apoptosis, DNA fragmenta-
tion was assessed following the method by Arai et al.
[30]. In brief, the cells were lysed in a lysis buffer (10
mM Tris, 1 mM EDTA, 0.2% Triton X-100, pH 7.5) and
centrifuged at 13,000 × g for 10 min. Subsequently, each
DNA sample in the supernatant and the pellet was pre-
cipitated in 12.5% trichloroacetic acid at 4°C and quanti-
fied using a diphenylamine reagent after hydrolysis in
5% trichloroacetic acid at 90°C for 20 min. After the
absorbance of the supernatant and the pellet was deter-
mined spectrophotometrically at a wavelength of 600
nm, the percentage of fragmented DNA in each sample
was calculated as the amount of DNA in the superna-
tant divided by the total DNA for that sample (superna-
tant plus pellet). The average percentage of fragmented
DNA in control samples was 2.7%.
Flow cytometry analysis
Cells were washed with FACS buffer (PBS, 1% bovine
serum albumin, 0.2% NaN3), stained with FITC-labeled
anti-human TNF-R1 antibody (clone MABTNFR1-B1;
BD Pharmingen, San Diego, CA) for 30 min at 4°C, fol-
lowed by phycoerythrin-labeled goat polyclonal anti-
mouse IgG (clone ab74490, Abcam, Cambridge, Eng-
land). Propidium Iodide (Sigma-Aldrich, St. Louis, MO)
was used to discriminate between dead and live cells.
Flow cytometric analysis was performed using FACSCa-
libur and Cell QuestPro software version 6.0 (BD Bios-
ciences, Franklin Lakes, NJ). TNF-R1 expression was
determined using mean fluorescence intensity (MFI),
with vehicle-treated cells as the baseline for all
comparisons.
Enzyme immunoassay for TNF-a
TNF-a concentrations were determined in cell culture
supernatants by enzyme-linked immunosorbent assay
(ELISA) (BioVender, Modřice, Česká republika). Sensi-
tivity of the assay was 4 pg/ml for TNF-a.N oc r o s s
reactivity was observed with other human inflammatory
cytokines including various interleukins. Optical density
was measured at 450 nm by use of a microplate reader.
Plasma levels of TNF-a were measured by the use of a
commercially available enzyme-linked assay kit (Shi-
bayagi Co. Ltd., Shibukawa, Japan) according to the
manufacture’s instructions.
Mouse model of type 2 diabetes
The animal study was carried out as approved by the
Animal Care and Use Committee of University of
Toyama. Male ICR mice, 5-weeks old, received an intra-
peritoneal injection of 1.5 g/kg body weight of nicotina-
mide dissolved in saline 15 min before a tail-vein
injection of streptozotocin (200 mg/kg; Sigma-Aldrich)
dissolved in a citrate buffer solution (0.1 M citric acid
and 0.2 M sodium phosphate, pH 4.5), following the
protocol previously reported [31,32]. Control mice
received the vehicles of both substances. The
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than a decade ago [33]. Its diabetic syndrome appears to
share a number of features with human type 2 diabetes
[31-33]. Animals were diabetic for 9 weeks before heart
harvest. Only animals with glycemia levels above 300
mg/dl were used for experiments.
Immunofluorescence and confocal analysis
Mouse hearts were harvested, fixed with 4% buffered
formalin solution, immersed in sucrose solutions, dipped
into OCT compound (Sakura Finetechnical, Tokyo,
Japan), and frozen at -20°C. The embedded tissues were
then sectioned at a thickness of 30 μm and air dried.
For immunohistochemical detection of the target mole-
cules, the tissue sections were exposed to the fluorescent
secondary antibody after incubation with the suitable
primary antibody according to the method in our pre-
vious study with minor modification [34]. Thus, rehy-
drated sections were incubated with the primary
antibody, anti-mouse CD31 (BD Pharmingen, Franklin
Lakes, NJ), anti-mouse TNF-R1 (BD Pharmingen), or
anti-mouse Fas (Merck KGaA, Darmstadt, Germany),
o v e r n i g h ta t4 ° C .T h ea n t i b o d i e sw e r eu s e da t1 : 1 0 0
dilution, followed by extensive washes with PBS and
incubation with the secondary antibodies conjugated to
high quality fluophores, including Alexa Fluor 568,
Alexa Fluor 488, and DyLight 488, at 1:500 dilution
overnight at 4°C. The nucleus was counterstained with
Hoechst 33258 (Nacalai Tesque, Kyoto, Japan). Immu-
nofluorescent images were observed under Leica TCS-
SP-5 confocal system (Leica, Wetzlar, Germany).
Statistical analysis
All experiments were performed at least three times.
Data are presented as means ± SE. Statistical assessment
of the data was made by one- or two-way ANOVA, and
then differences among groups were analyzed by Tur-
key’s multiple comparison test, with level of significance
set at P < 0.05.
Results
High glucose-induced endothelial cell apoptosis
The blood clotting protein vWF is synthesized and
secreted by endothelial cells. It is a useful maker for
endothelial cells, but appears to represent the presence
of vascular, especially endothelial, damage and play an
important role in thrombosis and inflammation [35].
Immunofluorescent staining for vWF showed that its
expression was markedly increased in HCAECs under
high glucose conditions (Figure 1). However, it should
b en o t e dt h a tt h i sw a so b s e r v e di nH C A E C sa tp a s s a g e
6~7 (used in this study) but not at passage 2, although
there was no obvious difference in morphology under
microscope observation up to passage 10 (data not
shown).
When cells were labeled with an in situ TUNEL
assay to detect apoptotic cells, exposure to high glu-
cose resulted in a striking appearance of TUNEL-posi-
tive cells (Figure 1). The merge image showed that a
positive TUNEL reaction was observed only in vWF
positive cells. To quantify high glucose-induced apop-
tosis, we measured DNA fragmentation in HCAECs.
As shown in Figure 2, exposure to high glucose
Normal
Glucose
5.6 mM
High
Glucose
16.7 mM
 
Hoechst TUNEL  vWF Isolectin B4 Merge 
100 μm
Figure 1 Effects of high glucose on expression of the inflammatory marker vWF and TUNEL staining-apoptosis in HCAECs. Cells were
treated with 16.7 mM glucose for 24 h. Endothelial cell apoptosis was labeled by the TUNEL reaction (green). vWF (red) and isolectin B4
(turquoise) were visualized by fluorescence microscopy. Isolectin B4 was used as a marker for endothelial cells. Nuclei were counterstained with
Hoechst (blue).
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on the concentration of glucose. Treatment with TNF-
a increased DNA fragmentation to the same extent as
16.7 mM glucose did. Combining TNF-a and high glu-
cose exhibited no additive effect compared with high
glucose alone.
To rule out an osmotic effect, we added 11 mM man-
nitol to 5.6 mM glucose. It was confirmed that mannitol
was without effect on either vWF expression or cell
apoptosis induction (data not shown).
Death receptor expression under high glucose
To determine how high glucose environment regulates
gene expression of death receptors in human endothelial
cells, the mRNA expression levels of TNF-R1, Fas, DR4,
and DR5 in HCAECs cultured for 24 h under high glucose
conditions were evaluated by PCR analysis (Figure 3).
High glucose exposure resulted in a concentration-depen-
dent increase in mRNA expression of TNF-R1. Mannitol,
used as an osmolarity control, had no effect on TNF-R1
mRNA expression (data not shown). Another death recep-
tor, Fas, was significantly increased under high glucose
conditions, although the extent of up-regulation was less
than that seen for TNF-R1. In contrast, mRNA expression
levels of DR4 and DR5, both of which mediate TRAIL
(TNF related apoptosis inducing ligand)-induced cell
death, under high glucose did not significantly differ from
those under normal glucose conditions.
Treatment with TNF-a (0.3 nM) strikingly up-regu-
lated mRNA expression levels of all death receptors
(Figure 3). High glucose-induced up-regulation of TNF-
R1 and Fas mRNA expression was concealed in the pre-
sence of TNF-a.
We characterized surface expression of TNF-R1 on
HCAECs using fluorescence flow cytometry (Figure 4).
Histograms generated by flow cytometry software
showed that a reproducible shift in TNF-R1 surface
expression compared to the mannitol-added control was
observed with exposure to high glucose. When TNF-a
was further treated under high glucose conditions, the
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Figure 2 Abilities of high glucose (11.1 and 16.7 mM) and TNF-a (0.3 nM) to induce apoptosis in HCAECs. The DNA fragmentation was
assayed as a biochemical hallmark of apoptosis. Values are expressed as mean ± SE (n = 3). **P < 0.01, ***P < 0.001 versus normal glucose (5.6
mM) without TNF-a.
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Figure 3 Abilities of high glucose (11.1 and 16.7 mM) and TNF-a (0.3 nM) to up-regulate gene expression levels of death receptors in
HCAECs. The mRNA levels of TNF-R1, Fas, DR4, and DR5 were analyzed by RT-PCR (A) and real-time PCR (B). Actin was used as a reference gene
for normalization of quantitative real-time PCR. Values are expressed as mean ± SE (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus normal
glucose (5.6 mM) without TNF-a.
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Figure 4 Representative histograms of HCAECs expressing TNF-R1. Surface expression of TNF-R1 was analyzed by flow cytometry using
FITC-labeled anti-human TNF-R1 antibody. Cells were treated with 16.7 mM glucose in the presence or absence of 0.3 nM TNF-a for 24 h.
Similar results were obtained with two additional experiments.
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not so pronounced.
Effect of TNF-R1 neutralizing peptides on high glucose-
induced apoptosis
TNF-a concentrations in cell culture supernatants were
measured with ELISA. ELISA analysis showed that, under
two high glucose conditions (11.1 and 16.7 mM), TNF-a
levels were increased about 3.5- and 5.5-fold, respectively,
compared to normal glucose medium (Figure 5A).
When TNF-R1 neutralizing peptides (80 nM) were
given during exposure to high glucose, DNA fragmenta-
tion caused by high glucose was significantly inhibited
b y2 3 %( F i g u r e5 B ) .W ec o n f i r m e dt h a tt h ep r e s e n c eo f
TNF-R1 neutralizing peptides (20, 40, and 80 nM)
inhibited TNF-a (0.3 nM)-induced DNA fragmentation
by 15, 38, and 52%, respectively.
Coronary expression of TNF-R1 and Fas in
type 2 diabetic mice
We generated type 2 diabetic mice which were adminis-
tered streptozotocin and partially protected with
nicotinamide. The non-fasting plasma glucose levels
were 149 ± 28 mg/dl (n = 4) and 583 ± 90 mg/dl (n =
5) for control and diabetic mice, respectively (p < 0.05).
Plasma TNF-a levels were much higher in diabetic than
in control mice (27.2 ± 5.4 vs 6.5 ± 2.7 pg/ml, p < 0.05).
Immunofluorescence staining for TNF-R1 and Fas in
the left ventricular cross-sections is shown in Figure 6.
Control mice had no positive staining for these death
receptors. On the other hand, appreciable positive stain-
ing was found in diabetic mice. Overlap images indi-
cated that both TNF-R1 and Fas were expressed on
coronary arterial endothelium.
Discussion
A growing body of evidence has shown that hyperglyce-
mia triggers various vascular endothelial dysfunctions
during the development of diabetes. Among them, high
glucose-induced endothelial cell apoptosis has been
noted in the pathogenesis of the acceleration of athero-
sclerosis associated with diabetes [6,9]. In the present
study, we also demonstrated that, in exposure to high
glucose for 24 h, HCAECs can undergo apoptotic cell
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Figure 5 TNF-a production and TNF-R1 neutralizing peptides-sensitive apoptosis in HCAECs under high glucose conditions. A: Effect of
high glucose on TNF-a levels in cell culture supernatants, analyzed by ELISA. Values are expressed as mean ± SE (n = 3). **P < 0.05, ***P < 0.01
versus normal glucose (5.6 mM). B: Effect of TNF-R1 neutralizing peptides on high glucose-induced endothelial cell apoptosis. TNF-R1 neutralizing
peptides (80 nM) were given in HCAECs treated with 16.7 mM glucose for 24 h. The DNA fragmentation was assayed as a biochemical hallmark
of apoptosis. Values are expressed as mean ± SE (n = 3). ***P < 0.001 versus control (normal glucose); ##P < 0.01 versus high glucose treatment
alone.
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Figure 6 Immunofluorescent images for TNF-R1 (A) and Fas (B) (green, white arrows) in the left ventricular cross-sections from control
and nicotinamide-streptozotocin-induced diabetic mice. Coronary arterial endothelial cells are stained with anti-CD31 antibody (red). Overlap
images indicate that both TNF-R1 and Fas are present on coronary arterial endothelial cells. Nuclei were counterstained with Hoechst (blue).
Shown are representative micrographs from two independent experiments in which the same results were obtained.
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mentation provides clear experimental evidence for high
glucose-induced apoptosis in HCAECs.
Previous works have indicated that high glucose treat-
ment increases Bax protein, an accelerator of apoptosis,
which in turn releases cytochrome c from mitochondria.
The released cytochrome c into cytoplasm can bind to
Apaf-1, resulting in activation of the caspase cascade
that induces apoptosis [21,22]. Thus, cytochrome c
released from mitochondria has been thought to be
important in high glucose-induced endothelial cell apop-
tosis. We found that gene and surface protein expres-
sion levels of TNF-R1 and Fas were highly up-regulated
in HCAECs under high glucose conditions. High glu-
cose-triggered death receptor up-regulation in human
endothelial cells was not due to changes in osmolarity,
because no increase in these death receptors was seen
in HCAECs treated with the osmotic control mannitol.
Furthermore, high ambient glucose did not lead to a sig-
nificant up-regulation of DR4 and DR5 in HCAECs,
both of which are known to be receptors for TRAIL
[36]. Our present findings would suggest the pathophy-
siological significance of the ligand-specific death recep-
tor apoptotic signaling pathway, in addition to the
intrinsic mitochondrial-mediated apoptotic signaling
pathway, in high glucose-induced human endothelial
cell apoptosis.
Apparent increases in plasma concentrations of proin-
flammatory cytokines, including TNF-a, seem to be
seen in subjects with obesity and insulin resistance [37].
It has been shown that expression of TNF-a as well as
other proinflammatory cytokines and chemokines is
regulated by glucose in human monocytes and monocy-
tic cell lines [38-40]. Thus, high glucose treatment acti-
vates these cells and induces an increase in gene
expression of TNF-a. We found that high glucose expo-
sure of HCAECs resulted in a marked increase in TNF-
a levels in cell culture supernatants. High glucose-
induced high expression of TNF-a has also been
demonstrated in cultured cardiomyocytes of neonatal
rats [41]. To the best of our knowledge, however, this is
the first to demonstrate the high glucose-induced
increases in TNF-a production by human endothelial
cells. In light of the up-regulation of TNF-R1, a mem-
brane receptor that mediates cytotoxicity elicited by
TNF-a, in HCAECs under high glucose conditions, we
interpret this finding to indicate that the TNF-a system
may play a key part in high glucose-induced endothelial
cell apoptosis.
Treatment with TNF-a in normal glucose medium
caused a marked up-regulation of mRNA levels of death
receptors in HCAECs. Therefore, TNF-a appears to be
a major determinant of high glucose-induced up-regula-
tion of TNF-R1 and Fas expression in endothelial cells.
Consistent with this is the finding that high glucose
resulted in no further up-regulation of TNF-R1 and Fas
mRNA expression in the presence of TNF-a. However,
high glucose-induced up-regulation of TNF-R1 and Fas
cannot be solely attributed to the increased TNF-a pro-
duction by endothelial cells exposed to high glucose.
Endothelial expression of DR4 and DR5 mRNAs was
strikingly up-regulated by TNF-a treatment but not by
high glucose exposure. Experimental evidence for the
regulatory mechanism(s) by which TNF-a can increase
gene expression of these TRAIL receptors awaits further
study.
A potential role of the TNF-a system in high glucose-
induced human endothelial cell apoptosis was tested
with TNF-R1 neutralizing peptides when given at a con-
centration of 80 nM. TNF-R1 neutralizing peptides
showed a significant inhibition of high glucose-induced
DNA fragmentation in HCAECs. This suggests that the
TNF-a system is involved in human endothelial cell
apoptosis induction under high glucose conditions.
However, the inhibitory effect of TNF-R1 neutralizing
peptides was less than 40%. It should be noted that the
dose of TNF-R1 neutralizing peptides employed in this
study caused >50% inhibition of 0.3 nM TNF-a-induced
DNA fragmentation in HCAECs. Alternatively, the Fas/
Fas ligand system as well as the intrinsic mitochondrial-
mediated apoptotic signaling pathway may be additional
mechanisms for the remaining effect of high ambient
glucose to induce human endothelial cell apoptosis. The
involvement of the Fas/Fas ligand system in high glu-
cose-induced apoptosis of human islets has been
demonstrated using the antagonistic anti-Fas antibody
ZB4 [42]. It may be considered that dual treatment with
TNF-R1 neutralizing peptide and ZB4 could suppress
high glucose-induced DNA fragmentation more effi-
ciently than TNF-R1 neutralizing peptide alone.
Exposure of endothelial cells to excess glucose has
been reported to induce inflammation [43,44]. The
underlying mechanisms are thought to be related to
accumulation of proinflammatory intermediates or by-
products such as reactive oxygen species. In this study,
the inflammatory marker vWF was strongly expressed in
HACECs when treated with high glucose. Importantly,
the merge image showed that a positive TUNEL reac-
tion was observed only in vWF positive cells. This
implies that apoptosis may be specifically induced in
inflammatory endothelial cells. In endothelial cells under
high glucose conditions, increased inflammation could
lead to enhanced apoptosis. Although the inflammatory
process involves the activation of the transcription factor
nuclear factor-B (NF-B) that is often associated with a
predominantly antiapoptotic role through its ability to
up-regulate cytoprotective gene products, the induction
of the potential regulator that globally induces
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mechanism to overcome NF-B-associated antiapoptosis
[45].
Finally, our immunofluorescence study found that
chronic type 2 diabetic mice showed appreciable expres-
sion of TNF-R1 and Fas in the intimal surface of coron-
ary arterioles. No positive staining for these death
receptors was obtained in age-matched control mice.
Circulating TNF-a levels were elevated in diabetic mice
as reported in diabetic patients as well as in streptozoto-
cin-induced diabetic rats [46,47]. Also, Fas ligand, whose
expression is limited to cells of the immunosystem, has
been shown to be significantly up-regulated in diabetic
rat neutrophils [48]. Therefore, induction of death
receptor expression in coronary arteriolar endothelium
may promote coronary endothelial cell apoptosis during
chronic diabetes. It is striking that there is a clinical
study showing increases in apoptosis of cardiomyocytes,
endothelial cells, and fibroblasts in specimens of myo-
cardial tissues from diabetic patients [11].
In conclusion, the present study showed that the
death receptors, TNF-R1 and Fas, are up-regulated in
HCAECs under high glucose conditions. This up-regula-
tion of death receptor expression, coupled with
increased TNF-a secretion, could promote endothelial
cell apoptosis, which is likely to contribute to coronary
arterial endothelial dysfunction and the development of
ischemic heart disease in diabetes.
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